David Speizman, DO
Internal Medicine · Boynton Beach, FLNPI 1952356685
Payments from drug & device makers
Across 221 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$598
- Amgen$395
- GSK$312
- Amarin Pharma, Inc.$302
- Johnson & Johnson$272
- AstraZeneca$246
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,02198%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $598 |
| Amgen | 24 | $395 |
| GSK | 17 | $312 |
| Amarin Pharma, Inc. | 17 | $302 |
| Johnson & Johnson | 15 | $272 |
| AstraZeneca | 14 | $246 |
| Abbott | 11 | $226 |
| Kowa Pharmaceuticals America, Inc. | 12 | $217 |
| Exact Sciences | 9 | $198 |
| Pfizer | 7 | $156 |
| Esperion Therapeutics, Inc. | 8 | $137 |
| Novartis | 8 | $132 |
| Bayer | 5 | $118 |
| AbbVie | 6 | $115 |
| Astellas Pharma US Inc | 2 | $105 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| Lilly USA, LLC | 4 | $78 |
| Merck | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$4,112 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $229,294 |
| JardianceEmpagliflozin | 61 | $91,736 |
| FarxigaDapagliflozin Propanediol | 64 | $84,828 |
| OzempicSemaglutide | 55 | $70,614 |
| XareltoRivaroxaban | 65 | $68,308 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $40,722 |
| RybelsusSemaglutide | 24 | $31,136 |
| LinzessLinaclotide | 31 | $30,040 |
| EntrestoSacubitril/Valsartan | 23 | $29,951 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $27,247 |
| JanuviaSitagliptin Phosphate | 23 | $27,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $24,787 |
| MyrbetriqMirabegron | 24 | $24,075 |
| TrulicityDulaglutide | 18 | $20,799 |
| Repatha SureclickEvolocumab | 11 | $16,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $156 | $229,294206 claims |
| Novo NordiskOzempic, Rybelsus | $598 | $101,75079 claims |
| Boehringer IngelheimJardiance | $24 | $91,73661 claims |
| AstraZenecaFarxiga | $246 | $84,82864 claims |
| Johnson & JohnsonXarelto | $272 | $68,30865 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $312 | $53,32985 claims |
| AbbVieLinzess, Synthroid | $115 | $33,21974 claims |
| NovartisEntresto | $132 | $29,95123 claims |
| MerckJanuvia | $68 | $27,10423 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $24,07524 claims |
| Lilly USA, LLCTrulicity | $78 | $20,79918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boynton Beach
- Debra WeinsteinBoynton Beach$14.8M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.